Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 20/20 | 0.73 |
| ▸ | CDK2 | P24941 | 20/20 | 0.73 |
| ▸ | KDR | P35968 | 16/20 | 0.73 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.73 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.73 |
| ▸ | CA2 | P00918 | 4/20 | 0.73 |
| ▸ | CDK4 | P11802 | 2/20 | 0.55 |
| ▸ | CDK7 | P50613 | 2/20 | 0.55 |
| ▸ | CDK9 | P50750 | 2/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.55 |
| ▸ | CCND1 | P24385 | 1/20 | 0.55 |
| ▸ | CCNH | P51946 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4582360 | 0.94 | CDK1 (0.78) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14112868 | 0.89 | CDK1 (0.71) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14112847 | 0.88 | CDK1 (0.68) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL4582885 | 0.88 | CDK1 (0.70) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14163276 | 0.88 | CDK1 (0.70) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL4057646 | 0.86 | CDK1 (0.82) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL13648309 | 0.86 | CDK1 (0.82) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14140920 | 0.86 | CDK1 (0.62) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14112814 | 0.85 | CDK1 (0.67) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14112850 | 0.84 | CDK1 (0.62) | CDK1CDK2KDRCCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1939185-A1 | New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939185-A1 | New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074515-A1 | NOVEL HETARYL-PHENYLENE-DIAMINE PYRIMIDINE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074515-A1 | NOVEL HETARYL-PHENYLENE-DIAMINE PYRIMIDINE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | CDK2, MKI67, ERBB2 | CDK1 16/4885CDK2 1/4885KDR 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.